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The success of immune checkpoint inhibitors in indu-
cing tumor regression has demonstrated that specific
inhibitory pathways are dominant rate-limiting steps in
a significant number of patients with melanoma and
other advanced cancers. However, in the majority of
patients tumor rejection is hindered by multiple immu-
nosuppressive mechanisms present in the tumor micro-
environment. Obstacles to immune-mediated tumor
control can be present at both the priming and effector
phase of the anti-tumor response, and include defective
function and activation of antigen-presenting cells,
defective T cell recruitment and infiltration of tumors,
and defective recognition and killing of cancer cells by
T cells. Ionizing radiation therapy (RT) applied locally to a
tumor at therapeutic doses has multiple effects that can
potentially overcome each of these obstacles, and we have
shown that RT is synergistic with immunotherapy. In pre-
clinical models RT converted tumors unresponsive to
anti-CTLA-4 mAb into responsive ones, achieving rejec-
tion of the irradiated tumor and non-irradiated metastases
(abscopal effect) and improved survival [1,2]. At the effec-
tor phase, RT enhanced recruitment of activated T cells to
the tumor by induction of chemokines [3], and enhanced
immune synapse formation between CD8 T and tumor
cells by induction of NKG2D ligands [4].
To test the hypothesis that successful tumor rejection
induced by RT+anti-CTLA-4 requires a significant change
in the quantity and quality of tumor-infiltrating lympho-
cytes (TILs) we performed a comprehensive evaluation of
the breadth and depth of the T cell repertoire modulated
by treatment using high-throughput sequencing technol-
ogy. To gain insights into the changes in TILs induced by
anti-CTLA-4 treatment in tumor hosts that respond or do
not respond to therapy we used our well-characterized
4T1 mouse model in which anti-CTLA-4 treatment is
effective only when combined with RT. Results show dis-
tinct contributions of RT and anti-CTLA-4 to increasing
the number and clonality of TILs, and changes in clonal
representation that are unique to the combination. These
data suggest that RT effectively releases endogenous
tumor antigens that prime anti-tumor T cells, supporting
the concept that it can be used as a mean to generate an
in situ individualized vaccine. We are currently exploring
this hypothesis in clinical trials testing the combination of
RT and checkpoint inhibitors.
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